QuantideX
®
Targeted NGS: An Integrated and Streamlined System for the Analysis of Low-Input FFPE and FNA Tumor DNA and RNA
Dr. Ravindra Kolhe, MD, PhD
Wednesday, November 18, 2015
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Talk Outline
NGS Constitutional Panels at GRU-GGC (2010-present)
Molecular Oncology Testing at GGC (Research Grant)
The QuantideX NGS Technology
QuantideX NGS – Full Integration of the NGS Library Prep Workflow
QuantideX NGS – The Impact of a Fully Integrated NGS Workflow
QuantideX NGS – NGS in a Box
The QuantideX NGS Pan Cancer Kit
Study Design
Clinically-Relevant Evaluation Samples from Multiple Sources
Performance
Study Performance – True FFPE Tumor Control
Study Performance – A Multi-variant Kit Control Provides Metrics for Batch Detection of Multiple Common Variants
Accuracy & Sensitivity – Detection of Mutations From FFPE Tumor Samples Down to 5% Frequency Using Targeted FFPE Blends
Multi-site variant quantification – Reproducibility Across 32 Matched FFPE Samples Tested at Both Sites
Reproducibility – Strong Uniformity and Precision Across Multiple Samples, Sites, Variant Types and Library Prep Runs
Accuracy – Variant Call Summary from Unique FFPE Specimens Shows Strong Concordance and Opportunities for Routine NGS
Results of the Study
Dr. Latham – QuantideX Targeted NGS
Unified, Targeted RNA and DNA Sequencing From Total Nucleic Acid
Frequency of Molecular Alterations in Lung Adenocarcinomas
Prototype Lung Cancer Targeted RNA-seq Panel
The Pan Cancer Kit Offers a Modular Workflow
Selection of a Stable Pan-Cancer Reference RNA
Coverage Uniformity for Multiplex PCR Enrichment
Cell-line Sensitivity for EML4-ALK Fusions
Residual Clinical FFPE Sensitivity for EML4-ALK Fusions
Unifying DNA and RNA Targets in a NSCLC NGS Panel
Multi-Omic Datasets from TNA Inputs on a MiSeq
With TCGA-Like Results
Summary
Acknowledgments
No transcript for this webinar
More Information
Request info